The OCTOVA Trial is open to recruitment at its first site. This multi-centre, randomised, open-label phase II trial will compare the activity and toxicity of chemotherapy (weekly Paclitaxel) to a novel agent Olaparib, and also Olaparib to the combination of Olaparib and Cediranib in women with advanced ovarian cancer and a gene mutation (BRCA gene). Olaparib is expected to be as active but less toxic than chemotherapy. This will be the first time that the combination of Olaparib and Cediranib has been tested in women with multiply relapsed platinum resistant ovarian cancer and a BRCA mutation.